DXCM News and Press, DexCom Inc. From 05/02/23

2023-05-02 07:25:43 ET DexCom ( NASDAQ: DXCM ) intends to offer $1B aggregate principal amount of convertible senior notes due 2028 in a private placement. Initial purchasers will be granted an option to purchase, within a 13-day period from up to an additional $150M princ...

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably beli...

2023-05-02 05:14:00 ET If you're a long-term Dexcom (NASDAQ: DXCM) shareholder, congratulations. A $1,000 bet placed on this developer of blood sugar monitoring devices a decade ago is worth nearly $30,000 today. Sadly, past performance doesn't guarantee future results. If anyth...

2023-04-28 15:33:38 ET Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q1 2023 Earnings Call Apr 27, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q1 2023 Earnings Call Transcript

2023-04-27 21:12:05 ET Dexcom, Inc. (DXCM) Q1 2023 Earnings Conference Call April 27, 2023, 16:30 ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, C...

2023-04-27 17:25:48 ET Citing Medicare coverage for its latest glucose monitoring device and strong Q1 2023 results, medical device maker, DexCom ( NASDAQ: DXCM ) increased its full-year outlook on Thursday following better-than-expected Q1 2023 results. During the quarter, the ...

2023-04-27 16:05:15 ET DexCom press release ( NASDAQ: DXCM ): Q1 Non-GAAP EPS of $0.17 beats by $0.02 . Revenue of $741.5M (+17.9% Y/Y) beats by $20.98M . 2023 Annual Guidance The company is updating fiscal year 2023 revenue guidance, and reiterating guid...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 ba...

2023-04-27 10:23:00 ET As a group, growth stocks had a year to forget in 2022. And even with the market recovery we are experiencing this year, many remain in the red over the past 12 months. But there are always outliers. Some growth stocks have performed just fine recently compared to the...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and Inuit peoples for improved diabetes management Dexcom, Inc. (NASDAQ: DXCM...